KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Interest & Investment Income (2017 - 2022)

Sarepta Therapeutics (SRPT) has 9 years of Interest & Investment Income data on record, last reported at $9.1 million in Q4 2022.

  • For Q4 2022, Interest & Investment Income rose 9506.32% year-over-year to $9.1 million; the TTM value through Dec 2022 reached $16.5 million, up 4557.63%, while the annual FY2023 figure was $36.3 million, 119.9% up from the prior year.
  • Interest & Investment Income reached $9.1 million in Q4 2022 per SRPT's latest filing, up from $4.8 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $9.1 million in Q4 2022 and bottomed at -$7.0 million in Q3 2018.
  • Average Interest & Investment Income over 5 years is $403400.0, with a median of $160500.0 recorded in 2021.
  • Peak YoY movement for Interest & Investment Income: plummeted 3886.96% in 2018, then surged 9506.32% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at -$2.3 million in 2018, then surged by 164.04% to $1.5 million in 2019, then plummeted by 95.2% to $71000.0 in 2020, then surged by 33.8% to $95000.0 in 2021, then soared by 9506.32% to $9.1 million in 2022.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $9.1 million in Q4 2022, $4.8 million in Q3 2022, and $2.4 million in Q2 2022.